Blinatumomab for treating acute lymphoblastic leukaemia in remission with minimal residual disease activity

Supporting evidence

• Evaluation report

• Final appraisal determination committee papers (PDF 4.99 MB)

  Published:

  24 July 2019

• Appraisal consultation committee papers (PDF 11.19 MB)

  Published:

  24 July 2019